epinamics – Drug delivery expertise from Germany
epinamics is a Berlin-based, privately owned research and development company, focusing on a patent protected drug delivery technology for dermal and transdermal applications of pharmaceutical and cosmeceutical products.
The polymer-based Liqui-Patch® is an invisible film-forming technology that can be combined with a broad range of (active) pharmaceutical ingredients. It is a unique platform technology that serves key patient needs of convenience, tolerability and safety in drug application.
Next to providing the actual drug delivery technology, epinamics is lending its pharmaceutical research and development expertise to support your company in getting innovative products to market. A team of industry experts will guide you from concept stage all the way to a fully approved product.
We would be very pleased to hear from you.
Excellent skin tolerance of epinamics’ Liqui-Patch technology
epinamics successfully completed a human clinical trial to evaluate the skin tolerability of their API-free Liqui-Patch® platform formulation. The placebo-controlled study investigated skin tolerability of API-free Liqui-Patch® in 20 healthy volunteers aged 18-65 over a 4 week period. Based on the observational 5-point IGA endpoint measurements, conducted at the Skin and Laser Centre (HLCP) in Potsdam/Germany, a 100% skin tolerance of the API free Liqui-Patch® formulation was demonstrated. The HLCP concluded that the Liqui-Patch® platform formulation is very well tolerated and safe in individuals 18 – 65 years of age.
In cooperation with international pharmaceutical companies, epinamics is developing two transdermal Liqui-Patch products for the treatment of Alzheimer’s and Parkinson’s disease as well as one dermal Liqui-Patch product for local treatment of fungal infections.
epinamics teams up with Aescuvest to raise 250´000 Euro for Parkinson study
epinamics has started a crowd-investing campaign with healthcare specialist Aescuvest to raise 250´000 Euros for a clinical bioavailability study of a potent dopamine agonist. The capital raised will be used to drive the existing development in transdermal treatment of Parkinson´s all the way to the registration stage. Epinamics´ transdermal application technology (Liqui-Patch®) thereby provides an easy to use, non-irritating and safe method to enhance the active agent’s penetration through the skin.
Please go to https://www.aescuvest.de/liqui-patch for further information about the campaign.
epinamics GmbH receives US-Patent on its Liqui-Patch® platform technology
The German biotech company epinamics was granted a patent for its Liqui-Patch® platform technology from the United States Patent and Trademark Office.
The innovative Liqui-Patch® technology was developed at epinamics` laboratories in Hermannswerder/Potsdam and serves the dermal and transdermal delivery of pharmaceutical ingredients. The polymer-based, film-forming and sprayable delivery technology can be formulated with a variety of pharmaceutical agents and has been shown in human pharmacology studies to be well tolerated.
In collaboration with global pharmaceutical companies epinamics GmbH is currently developing drugs for the treatment of dementia in Alzheimer’s and Parkinson’s patients.
Additional Liqui-Patch® patents for the European Union, Australia, Canada, China, Japan, South Korea, Mexico, Russia and South Africa had already been issued in recent years.
Epinamics signs development and licensing agreement with Libbs of Brazil
epinamics and Libbs Farmaceutica concluded a contract to develop and market the first transdermal Liqui-Patch product for the treatment of Alzheimer´s disease. Libbs has secured the rights to the product for the Latin American region including key markets Brazil and Mexico. “We are thrilled to move to the next level of transdermal application in such a key indication” said Dr. Giuliano Barissa, Business Development Manager at Libbs. For years the market is eager to bring forward new application methods that increase usability, tolerability and safety, altogether leading to a much better patient compliance. “The Liqui-Patch is providing all this and we are very proud to share our technology with a strong and experienced partner like Libbs” said Professor Kehr, CEO of epinamics.
Libbs Farmaceutica is a fully integrated pharma company headquartered in Sao Paulo, Brazil. Its 2´400 people strong staff focuses on all key indications in life science. The privately held company spends around 17% of its sales on research and development. For further details about Libbs please visit https://www.libbs.com.br/en .
Wolfgang Kehr, MD, PhD
Wolfgang Kehr gained more than 35 years of experience in leading positions in research, development, marketing and sales in the pharmaceutical industry, both in the United States and Europe.
At Schering AG he was in charge of global research of the pharmaceutical division and later headed the strategic business unit oncology and dermatology. At Berlex Laboratories, Inc. he was Vice President of Business Development and later General Manager of the cardiovascular and CNS Therapeutics Business. In his last position at Schering AG he was heading the dermatology unit which was spun out in 2005 as Intendis GmbH, with Wolfgang Kehr as President and CEO.
Since 2010 Prof. Dr. Wolfgang Kehr is CEO of epinamics GmbH.
Hans-Michael Thiede, MD
Hans-Michael Thiede’s scientific career started during the 1970s at Schering AG, where he developed his significant bioanalytical skills in toxicology and neuropharmacology.
From 1981 to 1991 he acquired extensive clinical experience in internal medicine, particularly in nephrology and cardiovascular diseases at the Charité – Campus Benjamin-Franklin. As the head of the local catecholamine laboratory, he investigated the role of catecholamine metabolism in essential hypertension which led to a number of bioanalytical innovations.
Hans-Michael Thiede developed a number of highly sensitive methods for the measurement of efficacy of active pharmaceutical ingredients. He continues his work as CEO at Thanares GmbH which he founded in Dresden in 2001 and which he later moved to Potsdam in 2007.
Since 2010 Hans-Michael Thiede is a partner and Chief Scientific Officer at epinamics GmbH.
Yan Luo, PhD
Yan Luo is a pharmaceutical chemist with 15 years of experience in research and development. From 2005 to 2007 Yan was research fellow at Queen’s University, Canada working on molecular cloning, expression, purification and characterization of bacterial enzymes. From 2006-2007 she was also doing research at Institute for Biological Science, National Research Council of Canada working on antibody engineering.
From 2008 –2016 Yan Luo was with Caprotec Bioanalytics GmbH in Berlin initially engaged in the development of new application fields for Caprotec’s technology as well as in molecular cloning, expression and purification of recombinant proteins.In 2015 she was promoted to group leader responsible for central project management of biomarker projects. In 2016 Yan joined epinamics as Head of Project Management. Yan Luo has significant expertise and experience in planning, coordination and execution of projects as well as in preparation of regulatory submissions to EMA and FDA.
Jonathan Turner, PhD
Jonathan Turner studied pharmacology and physiology and holds a PhD from St. Andrews. Jon has extensive industry experience in Pharma, Biotech and Finance. He was Global Director of Discovery Alliances at AstraZeneca PLC (UK) and Corporate Head of Pharmaceutical Licensing at Boehringer Ingelheim (Germany).
From 2012 to 2014 he was CEO of Caprotec Bioanalytics GmbH (Germany). Since 2016 Jon is Senior Partner at Portus Corporate Finance GmbH (Germany), responsible for M&A, successions and company founding for the Life Sciences industry. At epinamics Jon serves as an independent advisor focusing on Business Development and Finance.
Jost-Tilo Gehrke, PhD
Jost-Tilo Gehrke has a degree in business administration and systems science. He started his career in 1994 as financial controlling trainee at Gillette Europe in London. Thereafter, he worked as marketing controller and product manager for Gillette Germany. In 1999, Jost-Tilo moved to Novartis as marketing manager for the OTC-division, responsible for the buildup and management of global brands like Voltaren, Otrivin and Nicotinell.
As Global Head of Marketing, he joined Schering’s dermatology spin-off Intendis in 2005 where he was in charge of process planning, portfolio restructuring and strategic management of global brands in the area of Eczema, Acne, Psoriasis and Rosacea.
Since 2013, Jost-Tilo serves as advisor to epinamics focusing on Business development and Marketing.